雪榕生物发布前三季度业绩，净亏损6234.84万元

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 1.325 billion yuan, representing a year-on-year decrease of 19.26% [1] - The net loss attributable to shareholders of the listed company was 62.3484 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 85.1896 million yuan [1] - The basic loss per share was 0.11 yuan [1]